Article Figures & Data
Figures
- Figure 1.
OPSCC and proportion of HPV-associated cases in Giessen between 2000 and 2017. A, Annual number of HPV-negative and HPV-associated OPSCC diagnosed and treated at ENT-Giessen. B, Percentage of HPV-associated OPSCC treated at ENT-Giessen by year. C, Total number of oropharyngeal cancers and major subsites annually recorded by the local cancer registry in Giessen (GTD). Trend (lines) was estimated by linear regression, inclination- (“B”) and P values are listed in Table 1, significant deviation in inclination from constant values is indicated (*).
- Figure 2.
Age-adjusted annual incidence rates of oropharyngeal and cervical cancer in the United States and in Germany/Hesse. Trend (lines) was estimated by linear regression, inclination- (“B”) and P values are listed in Table 2, significant deviation in inclination from constant values is indicated (*).
- Figure 3.
Incidence trends in Germany, Hesse, and in the United States displayed according to gender (A) and major subsites of the oropharynx (B). Trend (lines) was estimated by linear regression, inclination- (“B”) and P values are listed in Table 2, significant deviation in inclination from constant values is indicated (*).
Tables
- Table 1.
HPV-prevalence and annual change in number of patients with oropharyngeal cancers and HPV-associated OPSCC in Giessen
2000–2017 Annual change Total Annual cases B (n; %) Mean (n) (Cases/year) P Local cancer registry All subsites 1111 (100.0%) 61.7 (±8.2) +0.787 0.029 Tongue 338 (30.4%) 18.8 (±5.2) −0.041 0.866 Gum & other mouth 118 (10.6%) 6.6 (±2.4) +0.000 1.000 Oropharynx & tonsil 655 (59.0%) 36.4 (±7.3) +0.829 0.007 Treated at ENT-Giessen All oropharyngeal cancers 730 (100.0%) 40.6 (±7.2) +0.718 0.029 HPV-negative 532 (72.9%) 29.6 (±5.1) −0.297 0.221 HPV-associated 198 (27.1%) 11.0 (±6.9) +1.015 <0.001 Abbreviations: B, Annual change in incidence (cases/year); P, P value calculated by linear regression, significant values in bold.
- Table 2.
Incidence trends of cervical and oropharyngeal cancers in the United States and Germany
Figure Cancer site Country B P Cervix Uteri United States −0.136 <0.001 Germany −0.113 <0.001 2 Oropharynx United States +0.101 <0.001 Germany +0.037 0.004 Hesse (Germany) −0.169 0.096 Subsite Country Gender B P Males +0.186 <0.001 United States Females +0.023 <0.001 Ratio males/females +0.032 <0.001 Males +0.021 0.190 3A Oropharynx (all subsites) Germany Females +0.046 <0.001 Ratio males/females −0.032 <0.001 Males −0.276 0.084 Hesse (Germany) Females −0.057 0.527 Ratio males/females −0.034 0.505 Both sexa +0.057 <0.001 United States Males +0.097 <0.001 Females +0.020 <0.001 Tongue Ratio males/females +0.026 <0.001 Both sexa +0.023 0.001 Germany Males +0.022 0.018 Females +0.022 <0.001 Ratio males/females −0.032 0.001 Both sexa +0.054 <0.001 United States Males +0.102 <0.001 Females +0.010 <0.001 3B Oropharynx & tonsil Ratio males/females +0.069 <0.001 Both sexa +0.002 0.628 Germany Males −0.002 0.779 Females +0.007 0.088 Ratio males/females −0.023 0.093 Both sexa −0.010 0.003 United States Males −0.013 0.006 Females −0.007 0.013 Gum & other mouth Ratio males/females −0.002 0.518 Both sexa +0.011 0.019 Germany Males +0.003 0.668 Females +0.017 <0.001 Ratio males/females −0.030 <0.001 Abbreviations: B, Annual change in incidence (per 100,000) or ratio (males/females); United States, SEER-database; Germany, RKI-database; P, P value calculated by linear regression, significant values in bold.
↵aNot displayed in figure.
Volume 12, Issue 6
